NeoGenomics, Inc. revised earnings guidance for the full year ending December 31, 2023. For the year, the company expected consolidated revenue to be in the range of $585 million to $592 million against the previous guidance range of $565 million to $575 million. Net loss to be in the range of $95 million to $89 million against the previous guidance range of $107 million to $100 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.16 USD | -0.60% | -3.59% | -11.93% |
02:05pm | NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO | CI |
02/05 | North American Morning Briefing : Stock Futures -3- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.93% | 1.82B | |
-24.63% | 7.83B | |
+70.13% | 4.32B | |
+1.53% | 2.63B | |
-7.18% | 2.53B | |
-44.62% | 2.29B | |
-19.46% | 1.51B | |
+18.85% | 1.22B | |
-43.60% | 1.17B | |
+17.33% | 957M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023